Targeting the Oxytocin System: New Pharmacotherapeutic Approaches

Trends Pharmacol Sci. 2019 Jan;40(1):22-37. doi: 10.1016/j.tips.2018.11.001. Epub 2018 Nov 30.

Abstract

Deficits in social behavioral domains, such as interpersonal communication, emotion recognition, and empathy, are a characteristic symptom in several neuropsychiatric disorders, including schizophrenia and autism spectrum disorder (ASD). The neuropeptide oxytocin (OT) has emerged as a key regulator of diverse social behaviors in vertebrates and, thus, has been identified as a potential therapeutic target for improving social dysfunction. In recent years, the field of OT research has seen an explosion of scientific inquiry, producing a more comprehensive picture of oxytocinergic signaling and the pathways that regulate its release and degradation in the brain. In this review, we provide an analysis of how this information is being exploited to accelerate the discovery of novel oxytocinergic therapeutics.

Keywords: drug development; neuropsychiatric disease; oxytocin; social cognition.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Brain / metabolism
  • Drug Discovery / methods*
  • Humans
  • Mental Disorders / drug therapy
  • Mental Disorders / physiopathology
  • Oxytocin / metabolism*
  • Signal Transduction / physiology
  • Social Behavior
  • Social Behavior Disorders / drug therapy*
  • Social Behavior Disorders / etiology
  • Social Behavior Disorders / physiopathology

Substances

  • Oxytocin